A network pharmacology integrated serum pharmacochemistry strategy for uncovering efficacy of YXC on hepatocellular carcinoma.

J Ethnopharmacol

The First School of Clinical Medicine, Nanjing University of Chinese Medicine, 210023, Nanjing, China; Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, 210023, Nanjing, China; Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumour, 210023, Nanjing, China. Electronic address:

Published: January 2024

AI Article Synopsis

  • The YangzhengXiaoji capsule (YXC) is a traditional Chinese medicine showing promise in treating hepatocellular carcinoma (HCC), though its active components and mechanisms are not fully understood.
  • This study aimed to uncover the treatment mechanisms of YXC on HCC using network pharmacology and advanced serum analysis in nude mice with liver tumors.
  • Results revealed 47 bioactive compounds in YXC and identified 173 target genes, with significant effects on cancer-related pathways; YXC demonstrated strong anti-cancer properties both in vitro and in vivo.

Article Abstract

Ethnopharmacological Relevance: The YangzhengXiaoji capsule (YXC) has a wide range of applications as effective traditional Chinese medicine (TCM) preparation for hepatocellular carcinoma (HCC) in China. However, the potential bioactive components and the mechanisms are yet unclear.

Aim Of The Study: The treatment mechanism of YXC on HCC using a network pharmacology integrated serum pharmacochemistry strategy to investigate associated targets and pathways.

Materials And Methods: We utilised HPLC-Q-TOF-MS/MS technology to identify components of the serum samples from both the model group and the YXC (H) group serum, which were collected from nude mice with orthotopic liver tumours. Following this, we conducted compound-target prediction and identified the overlap between the target genes in the YXC group and the oncogenes associated with HCC. The anticancer mechanisms of YXC were investigated by creating a compound-target-pathway network using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) analysis. The anticancer efficacy was evaluated in vitro and in vivo. Also, potential predictive targets and pathways associated with YXC in HCC treatment were assessed by western blotting.

Results: The YXC (H) serum had 47 bioactive compounds compared to other models, and identified 173 specific target genes. Using the compound-target-disease network, 141 possible target genes were identified. The KEGG pathway analysis revealed vital enrichment of pathways associated with HCC, including regulating Oncology related pathways of inflammation, immunity, apoptosis, and necrosis biological processes. YXC significantly inhibited HCC cell growth in vitro and in vivo. After YXC treatment, western blotting detected alterations in the p53/Bcl-2/Bax/Caspase-3 and PI3K/Akt pathways.

Conclusions: YXC can inhibit HCC development and advancement by a variety of components, targets and pathways, especially apoptosis-induction.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jep.2023.117125DOI Listing

Publication Analysis

Top Keywords

target genes
12
yxc
11
network pharmacology
8
pharmacology integrated
8
integrated serum
8
serum pharmacochemistry
8
pharmacochemistry strategy
8
hepatocellular carcinoma
8
yxc hcc
8
yxc group
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!